Elutia reports Q3 EPS (19c) vs. (33c) last year

Reports Q3 revenue $3.3M vs. $3.6M last year. “Behind every breast reconstruction is a woman overcoming cancer,” said Randy Mills, CEO of Elutia (ELUT). “Incredibly, infection remains one of the biggest barriers to recovery, impacting 15-20% of reconstruction cases. Our antibiotic-eluting technology is designed to prevent infection from occurring in the first place. The Elutia CRU is laser-focused on this goal, fully resourced, and moving fast to deliver a game-changing solution that helps women everywhere thrive without compromise.”